$1.14-0.02 (-1.72%)
Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.14 with a market capitalization of $6M. The stock is currently near its 52-week low of $0.85, remaining 55.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.56Mβ | $4.35Mβ | $5.60Mβ | $4.01Mβ | $3.75M |
| Gross Profit | $2.18Mβ | $1.65Mβ | $2.12Mβ | $1.46Mβ | $1.53M |
| Operating Income | -$351,000β | -$678,000β | -$337,000β | -$1.09Mβ | -$656,000 |
| Net Income | -$581,000β | -$819,000β | -$534,000β | -$1.24Mβ | -$776,000 |
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America...
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Walmart, Amazon Deal Sends Sonoma Pharmaceuticals Stock Into Frenzy
Nu Holdings Ltd. 57,985,829 12.32